Glucotrack (Nasdaq:GCTK) announced that it appointed Drinda Benjamin as its new vice president of marketing.
Rutherford, New Jersey-based Glucotrack develops an implantable continuous glucose monitor (CGM). It designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. A recent feasibility study demonstrated reliable glucose measurements for two years post-implant for the device.
Benjamin brings more than 20 years of experience in life sciences to Glucotrack, with focus on commercializing health technology. She has past experiences in product development, strategic marketing and more in the diabetes space. That includes work with blood glucose monitoring, CGM, insulin delivery and closed-loop systems.
Responsibilities for Benjamin at Glucotrack include go-to-market strategy, marketing operations, communications, public relations and market access strategy.
“I am thrilled to be a part of the dedicated Glucotrack team,” Benjamin said in a news release. “Innovations in glucose monitoring have significantly improved quality of life for people with diabetes. But there still is an opportunity to build upon current technologies and bring new ones to the millions of people living with diabetes.
“Glucotrack’s early data shows great promise to deliver on that opportunity.”
More about the experience Drinda Benjamin brings to Glucotrack
Most recently, Benjamin worked at Intuity Medical, developing and executing commercial strategies for a blood glucose monitoring system. Before that, she led business development, partnership strategy and closed-loop system programs for Senseonics. Senseonics developed the first implantable CGM launched in the U.S. and Europe.
Other previous roles for the new VP of marketing at Glucotrack include marketing stints with the diabetes units at Abbott and Medtronic.
“We are excited that Drinda has joined our growing company in this important leadership role.” said Paul Goode, CEO of Glucotrack. “She brings a wealth of first-hand experience in product and strategic development within the diabetes space, particularly with spot-measurement BGM and implantable CGM.
“As we continue our product development and prepare for commercialization, we are pleased to have Drinda join to help the company bring our innovative technology to people with diabetes.”